Corresponding to this data, we showed in a preclinical study with different ovarian cancer cell lines that dual anti-EGFR blockade led to neither synergistic antiproliferative effect in anti-EGFR-sensitive cells nor de novo anti-EGFR sensitivity in anti-EGFR-resistant cell lines [24]. Here, EGFR is linked to ovarian cancer.